FDA approves Moderna's mRNA flu shot after turbulent review

The FDA has approved Moderna's mRNA-based influenza vaccine, marking the second mRNA vaccine authorized for use after its COVID-19 shot. The approval follows a review process that included setbacks and reconsideration of trial data. This decision expands mRNA technology to seasonal flu prevention, offering a potentially faster and more adaptable vaccine platform.

Sources (1)